Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
(Q34633455)
scientific article
scientific article
Language:
Current Data About
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
other details
| description | scientific article |
External Links
| (P356) |
10.1158/1078-0432.CCR-11-1491
|
| (P698) |
22048237
|
| (P932) |
3549298
|
| (P8608) |
release_ytcsa3j64zfblfntylsgh63aiu
|